LianBio CFO Yi Larson resigns; Ehong Gu named interim CFO

LianBio

Yi Larson resigned as CFO effective December 19, 2023, to pursue other opportunities.
Separation agreement provides severance of $2,430,124 paid in installments and lump sum.
Ehong Gu, VP Head of Global Finance, appointed interim CFO as principal financial officer.
Gu has held senior finance roles at CStone, BeiGene, and Celgene; no compensation terms set yet.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Ehong Gu

Interim Chief Financial Officer

LIANY · LianBio

Effective: 2023-12-19
Filed: December 20, 2023, 6:59 PM ET

In connection with Ms. Larson’s departure, effective December 19, 2023, the Board appointed Ehong Gu as Interim Chief Financial Officer of the Company, in which role she will act as the Company’s principal financial officer and principal accounting officer.

Departed

Yi Larson

Chief Financial Officer

LIANY · LianBio

Effective: 2023-12-19
Successor: Ehong Gu
Filed: December 20, 2023, 6:59 PM ET

Yi Larson, the Company’s Chief Financial Officer, has decided to resign from the Company, effective December 19, 2023, to pursue other business and professional interests and opportunities.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ehong Gu was appointed as Interim Chief Financial Officer at LianBio.

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

In connection with Ms. Larson’s departure, effective December 19, 2023, the Board appointed Ehong Gu as Interim Chief Financial Officer of the Company, in which role she will act as the Company’s principal financial officer and principal accounting officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Yi Larson resigned as Chief Financial Officer at LianBio.

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

Yi Larson, the Company’s Chief Financial Officer, has decided to resign from the Company, effective December 19, 2023, to pursue other business and professional interests and opportunities.

View on SEC.gov

LianBio filing history →

Source: SEC EDGAR

accession 0001831283-23-000141

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.